EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A rapid HPV typing assay to support global cervical cancer screening and risk‐based management: A cross‐sectional study

Federica Inturrisi iD, Silvia de Sanjosé, Kanan T Desai, Casey Dagnall, Didem Egemen, Brian Befano, Ana Cecilia Rodriguez, Jose A Jeronimo, Rosemary E Zuna, Amanda Hoffman, Sepideh Farhat Nozzari, Joan L Walker und 4 weitere

International Journal of Cancer · 15.01.2024 · 154 (2) · 241-250

DOI: 10.1002/ijc.34698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 29.09.2023. Verfasst von Federica Inturrisi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Uterine Cervical Dysplasia, Papillomavirus Infections. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, Division of Cancer Epidemiology and Genetics, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The World Health Organization recommends human papillomavirus (HPV) testing for cervical screening. Extended genotyping can identify the highest‐risk HPV‐positive women. An inexpensive, rapid, mobile isothermal amplification assay (ScreenFire HPV RS test) was recently redesigned to yield four channels ordered by cancer risk (ie, hierarchical approach): HPV16, HPV18/45, HPV31/33/35/52/58 and HPV39/51/56/59/68. Stored specimens from 2076 women (mean age 30.9) enrolled in a colposcopy clinic, with high HPV prevalence, were tested with ScreenFire. We calculated hierarchical channel positivity and non‐hierarchical channel and type positivity, according to histologic diagnosis (256 cancer, 350 cervical intraepithelial neoplasia [CIN]3, 409 CIN2, 1020 < CIN2) and known virologic reference results (Linear Array and TypeSeq). Additionally, we analyzed ScreenFire time‐to‐positive up to 60 min by channel and histology. Overall clinical sensitivity for CIN3+ was 94.7% (95% confidence interval 92.6‐96.4), similar to Linear Array (92.3, 89.7‐94.3) and TypeSeq (96.0, 93.9‐97.6). Sensitivity was high for all types and channels. The hierarchical approach was well in line with HPV typing and histologic diagnosis, prioritizing higher risk women having HPV16 and precancer. For HPV16, time‐to‐positive was shorter in women with precancer. ScreenFire showed excellent agreement with research reference typing tests and detection of CIN2+. Risk‐based type results could help guide clinical management of HPV‐positive women. Time‐to‐positive combined with genotyping might be useful. ScreenFire is rapid, mobile, relatively inexpensive and designed for implementation of HPV‐based screening and management, including in lower‐resource settings. Further validation in screening by self‐sampling and practical effectiveness merit evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsUterine Cervical DysplasiaPapillomavirus InfectionsAdultHuman papillomavirus 16Cross-Sectional StudiesHuman papillomavirus 18FemaleHumansPapillomaviridaeEarly Detection of CancerGenotype

Stichwörter der Autor:innen

HPV genotypingHPV testingLMICcervical cancer screeningrisk-stratification

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
  • ISGlobal, Barcelona, Spain.
  • Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
  • Information Management Services Inc., Calverton, Maryland, USA.
  • Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA.
  • Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

ORCID-Profile: Federica Inturrisi, Nicolas Wentzensen

Förderung

  • Intramural NIH HHS
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute

Zitieren

APA

Inturrisi, F., de Sanjosé, S., Desai, K. T., Dagnall, C., Egemen, D., Befano, B., Rodriguez, A. C., Jeronimo, J. A., Zuna, R. E., Hoffman, A., Farhat Nozzari, S., Walker, J. L., Perkins, R. B., Wentzensen, N., Palefsky, J. M., & Schiffman, M. (2024). A rapid HPV typing assay to support global cervical cancer screening and risk‐based management: A cross‐sectional study. International Journal of Cancer, 154(2), 241-250. https://doi.org/10.1002/ijc.34698

Vancouver

Inturrisi F, de Sanjosé S, Desai KT, Dagnall C, Egemen D, Befano B, et al. A rapid HPV typing assay to support global cervical cancer screening and risk‐based management: A cross‐sectional study. International Journal of Cancer. 2024;154(2):241-250. doi:10.1002/ijc.34698

BibTeX
@article{Inturrisi2024,
  author = {Inturrisi, Federica and de Sanjosé, Silvia and Desai, Kanan T and Dagnall, Casey and Egemen, Didem and Befano, Brian and Rodriguez, Ana Cecilia and Jeronimo, Jose A and Zuna, Rosemary E and Hoffman, Amanda and Farhat Nozzari, Sepideh and Walker, Joan L and Perkins, Rebecca B and Wentzensen, Nicolas and Palefsky, Joel M and Schiffman, Mark},
  title = {A rapid HPV typing assay to support global cervical cancer screening and risk‐based management: A cross‐sectional study},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {154},
  number = {2},
  pages = {241--250},
  doi = {10.1002/ijc.34698}
}
Kostenlos starten →